ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1811

Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity

Alejandra Maria Patiño-Trives1, Concepción Aranda-Valera2, R Roldan3, Laura Pérez-Sanchez4, Carlos Pérez-Sánchez1, Maria Luque-Tevar1, Iván Arias de la Rosa1, María-Carmen Abalos-Aguilera1, Desirée Ruiz-Vilchez2, Pedro Segui5, Mario Espinosa5, Nuria Barbarroja1, Eduardo Collantes2, María de los ángeles Aguirre-Zamorano5 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 3Hospital Universitario Reina Sofía, Cordoba, Spain, 4Hospital Universitario Reina Sofía, Córdoba, Spain, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba

Meeting: ACR Convergence 2020

Keywords: Atherosclerosis, Inflammation, Juvenile Rheumatoid Arthritis, Lupus nephritis, lupus-like disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: By using integrative transcriptomic and protein analyses, this study aimed at identifying and characterize distinctive molecular signatures between childhood-onset (cSLE) and adult-onset Lupus (aSLE) patients, along with their involvement in immunological and clinical features, and to analyze the relevance of the sustained positivity for anti-dsDNA antibodies.

Methods: Ninety-four subjects were enrolled, comprising two main combined study groups: 1) eleven consecutive children with pediatric-onset SLE (cSLE) and 11 age and sex matched healthy children (cHD); 2) sixty aSLE patients and 20 healthy adults (aHD). Total RNA was extracted from purified monocytes and pools from 5 subjects of each study group were obtained. Then, a nanostring autoimmune profiling array was used for mRNA expression data generation.

Results: Gene expression array identified 279 altered genes in monocytes from cSLE vs cHD. Comparatively, less than a half of genes (130) were found altered in monocytes from aSLE vs aHD. The analysis of common altered genes between the two study groups revealed 19 genes as upregulated in both patients’ cohorts. Interestingly, Gene Ontology enrichment analysis identified as main biological processes integrated by these genes the interferon signature (IFNs). Moreover, cSLE displayed at least a double fold change in the levels of these genes vs cHD than aSLE vs aHD.

Correlation and association studies demonstrated that in the cSLE cohort the altered expression of a number of genes integrating the IFNs was linked to several clinical features. Specifically, increased levels of IFI27 were associated to the occurrence of lupus nephropathy (LN) and positivity for anti-dsDNA, and correlated positively with the activity of the disease (SLEDAI), CV-risk factors (atherogenic index and ApoB/ApoA ratio) and plasma levels of proteins of the IFN family such as IP-10.

Accordingly, in aSLE, altered expression of IFNs was associated to the presence of LN and low levels of complement factors C3 and C4, as well as to increased plasma levels of IFNγ. Interestingly, most of them were further associated with the positivity for anti-dsDNA. A deeper study in this cohort demonstrated that a third of the aSLE patients’ displayed a sustained positivity for anti-dsDNA for more than 7 years. Moreover, these patients showed altered expression of several IFN genes, and presented LN along with a pathologic increase in the Carotid Intimae Media Thickness, and impaired microvascular endothelial function, thus supporting the potential role of the IFNs in the severity of the disease and the development of cardiovascular disease.

Conclusion: 1. Gene expression profile allowed the identification of distinctive molecular pathways among monocytes of cSLE and aSLE 2. An interferon signature, more strongly  deranged in cSLE than in aSLE patients, is closely related to the activity of the disease and the renal involvement. 3. The sustained positivity for anti-dsDNA in aSLE, further linked to that deranged IFNs and to the development of lupus nephritis, might fosters the establishment of an atherothrombotic status in these autoimmune patients.

Supported by ISCIII (PI18/0837 and RIER RD16/0012/0015), Co-funded with FEDER.


Disclosure: A. Patiño-Trives, None; C. Aranda-Valera, None; R. Roldan, None; L. Pérez-Sanchez, None; C. Pérez-Sánchez, None; M. Luque-Tevar, None; I. Arias de la Rosa, None; M. Abalos-Aguilera, None; D. Ruiz-Vilchez, None; P. Segui, None; M. Espinosa, None; N. Barbarroja, None; E. Collantes, Abbvie Inc, 5, 8, Amgen, 5, 8, Eli Lilly and Company, 5, 8, Janssen Pharmaceutical, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer Inc, 5, 8, UCB, 5, 8; M. Aguirre-Zamorano, None; C. Lopez-Pedrera, None.

To cite this abstract in AMA style:

Patiño-Trives A, Aranda-Valera C, Roldan R, Pérez-Sanchez L, Pérez-Sánchez C, Luque-Tevar M, Arias de la Rosa I, Abalos-Aguilera M, Ruiz-Vilchez D, Segui P, Espinosa M, Barbarroja N, Collantes E, Aguirre-Zamorano M, Lopez-Pedrera C. Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/distinctive-molecular-signatures-among-monocytes-from-childhood-and-adult-onset-systemic-lupus-erythematosus-clinical-involvement-and-relevance-of-sustained-anti-dsdna-positivity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinctive-molecular-signatures-among-monocytes-from-childhood-and-adult-onset-systemic-lupus-erythematosus-clinical-involvement-and-relevance-of-sustained-anti-dsdna-positivity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology